Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Kidney Int. 2017 Dec 28;93(3):691–699. doi: 10.1016/j.kint.2017.09.027

Table 2.

Distribution of CKD stages at baseline and after 12 years of follow-up

Renal insufficiency endpoint Baseline no. (%) Year 12 no. (%)
Measured GFR (iothalamate)
 >90 (CKD Stage 1) 135 (56.0) 32 (14.2)
 60–89 (CKD Stage 2) 94 (39.0) 81 (35.8)
 30–59 (CKD Stage 3) 12 (5.0) 55 (24.3)
 15–29 (CKD Stage 4) 0 (0.0) 16 (7.1)
 <15 (CKD Stage 5) or ESRD 0 (0.0) 42 (18.6)
 GFR decreased ≥ 30% 143 (71.1)
 GFR decreased ≥ 57% 76 (40.4)

eGFR (MDRD formula)
 >90 (CKD Stage 1) 96 (39.8) 12(5.2)
 60–89 (CKD Stage 2) 121 (50.2) 92 (39.7)
 30–59 (CKD Stage 3) 24 (10.0) 64 (27.6)
 15–29 (CKD Stage 4) 0 (0.0) 22 (9.5)
 <15 (CKD Stage 5) or ESRD 0 (0.0) 42 (18.1)
 GFR decreased ≥ 30% 139 (67.5)
 GFR decreased ≥ 57% 77 (38.7)

eGFR (CKD-EPI formula)
 >90 (CKD Stage 1) 121 (50.2) 20 (8.9)
 60–89 (CKD Stage 2) 102 (42.3) 80 (35.6)
 30–59 (CKD Stage 3) 18 (7.5) 57 (25.3)
 15–29 (CKD Stage 4) 0 (0.0) 26 (11.5)
 <15 (CKD Stage 5) or ESRD 0 (0.0) 42 (18.7)
 GFR decreased ≥ 30% 140 (70.0)
 GFR decreased ≥ 57% 79 (39.7)

GFR values in mL/min/1.73 m2